HAI Book 2025 - Flipbook - Page 264
Wednesday, January 15, 2025 - 02:00 pm - 02:30 pm
Kolb, Hartmuth
Keynote: From click chemistry to precision neuroscience
Hartmuth Kolb
Enigma Biomedical Group
This presentation highlights the transformative role of click
chemistry in the development of molecular imaging probes,
including the Tau PET tracers, ¹⁸F-T807 (aka AV1451,
Flortaucipir, Tauvid) and ¹⁸F-T808. PET imaging of Alzheimer9s
disease pathology has been instrumental for developing the
biomarker-driven framework for diagnosis and staging of the
disease, which has catalyzed the advent of the first diseasemodifying therapies. We will discuss the integration of fluid
assays and imaging workflows into clinical trials and how
some of these measurements even function as reasonably
likely surrogate endpoints. Looking forward, emerging
imaging techniques targeting pathological proteins such as
TDP-43 and a-Synuclein, as well as neuroinflammatory
processes, promise to expand the scope of
neurodegenerative disease research. Together, these
advances empower patient-centric precision medicine,
driving innovation in neuroscience diagnostics and
therapeutics.
Dr. Hartmuth Kolb received his PhD in Organic
Chemistry in 1991 at Imperial College of Science,
Technology and Medicine, London. He joined
Ciba-Geigy in 1993 and in 1997 became VP of
Chemistry at Coelacanth Corporation to work
with K. Barry Sharpless on pioneering Click
Chemistry.
Dr. Kolb was the first author of the first
publication on this topic (2022 Chemistry Nobel
Prize for Sharpless, Meldal and Bertozzi). He
then became head of Siemens Biomarker
Research, where he and his team developed PET
tracers using Click Chemistry. The PET tracer
[18F]-T807 (aka
